| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.002 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.2 | 0.002 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.19 | 0.002 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | serdemetan:SCH-529074 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.12 | 0.003 |